Many pharma organizations face a critical challenge post manufacturing execution system (MES) deployment: value delivered at the time of launch is often limited to technical functionality, falling short of the broader, business-aligned impact the system is capable of delivering. This gap is often the result of an implementation plan that ends at go-live, as well as an insufficient measurement system. While the initial MES deployment is often well-resourced, the post-implementation phase is frequently underemphasized, leading to underutilized features, limited user engagement, and missed opportunities for operational improvement. At the same time, the role that MES plays in the business is evolving. To unlock MES’s full potential, pharma organizations must rethink the system’s role, applications, measurement, and possibilities: Deployment is not the finish line—it’s the starting point. In this paper, our experts examine how pharma companies, as well as biopharma and other life sciences organizations, can embrace this new vision of MES to avoid the post-launch plateau and harness the full power of their investment.

Join for free to read